Study: Patients with knee OA may have neuropathic pain | MRIs show opioid-addicted pain patients respond to therapy | Neuroimaging may give clues to cause of fibromyalgia
Web Version
September 24, 2014
News for the pain professional

Pain Research NewsAdvertisement
Study: Patients with knee OA may have neuropathic pain
A U.K. study found some patients with knee osteoarthritis may have neuropathic symptoms linked to central pain processing, which may increase the severity of their pain and add to "overlapping pain qualities associated with either nerve or joint damage." Two assessment tools may help classify this type of pain, researchers wrote in the journal Arthritis Care & Research, but there still are questions about the relationship among knee osteoarthritis, neuropathic pain and central pain processing. MedWire News (U.K.) (9/22)
Share: LinkedInTwitterFacebookGoogle+Email
MRIs show opioid-addicted pain patients respond to therapy
University of Texas researchers used MRIs to map regional brain activity linked to pain severity in patients with opioid addiction and chronic lower back pain, and then monitor changes after psychotherapy. Follow-up scans showed patients who underwent Acceptance and Commitment Therapy had decreased activity in response to pain compared with a control group, according to a study presented at the American Academy of Pain Management's annual meeting. Medscape (free registration) (9/22)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
How will you meet CMS guidance on IV opioids?
The Joint Commission's Sentinel Event Alert on the safe use of opioids in hospitals recommends continuous oxygenation and ventilation monitoring of patients receiving opioids. Masimo Patient SafetyNet and Masimo SET® enabled Dartmouth-Hitchcock Medical Center to significantly improve clinical outcomes and reduce the cost of care. Learn how here.
*The use of the trademark SafetyNet is under license from University HealthSystem Consortium.
Treatment News
FDA study finds nerve stimulators can help treat migraines
An FDA study found that the Cerena transcranial magnetic stimulator and the Cefaly transcutaneous electrical nerve-stimulation system can provide relief from migraines in patients who have failed to respond to medications. The Cerena device is intended for use at the onset of a migraine, and the Cefaly system is used to prevent it. Both devices already have been approved by the FDA. HealthDay News (9/22)
Share: LinkedInTwitterFacebookGoogle+Email
Study: Acupuncture effective, cost-effective in treating osteoarthritis
A meta-analysis found that acupuncture was effective in reducing pain, improving mobility and enhancing quality of life among osteoarthritis patients. The Canadian researchers reviewed 12 separate trials covering 1,763 patients and found that acupuncture was safe and effective in treating osteoarthritis, as well as being a cost-effective approach. HealthCMi (9/19)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Policy & Trends
Group calls for replacing FDA head over opioid drug approvals
The advocacy group Fed Up! is calling for FDA Commissioner Dr. Margaret Hamburg to lose her job over the approval of opioid drugs. The group of physicians, addiction specialists and families of overdose victims said it was frustrated that FDA has continued to approve new high-dose opioids. The agency said Hamburg has been a "tireless public health advocate." Hamburg has said the agency is committed to addressing opioid abuse as well as the needs of patients with chronic and severe pain. The Washington Post (tiered subscription model) (9/24)
Share: LinkedInTwitterFacebookGoogle+Email
Hydrocodone reclassification might have unintended consequences
Effective Oct. 6, drugs containing hydrocodone will be reclassified as Schedule II substances. Nurses and nurse practitioners will no longer be allowed to write prescriptions for the drugs, prescribers will no longer be allowed to call in prescriptions, pharmacies will have to keep the drugs in special vaults, and prescriptions will be restricted to a single 90-day supply with no refills unless the patient visits a health care provider. The rules are meant to reduce addiction and abuse, but they are likely to raise prices for consumers and payers, Edward Lawrence writes. RxObserver blog (9/18)
Share: LinkedInTwitterFacebookGoogle+Email
APS News
LOI deadline for Keller Research Grant Program is Tuesday
The Sharon S. Keller Chronic Pain Research Grant Program LOI deadline is Tuesday, Sept. 30. The purpose of the Keller Grant Program is to fund research projects that investigate the effectiveness of nonpharmacologic treatments for pain, and mechanisms underlying these treatments. Proposed research projects should investigate non-invasive interventions with favourable side effect profiles to improve chronic management. The APS Sharon S. Keller Chronic Pain Research Grant may award up to three grants in the amount of $35,000 to those pain research proposals that demonstrate the greatest merit and potential for success. Interested applicants should submit a one-page LOI briefly describing the objective, aims, methods and relevance of their proposed. Only approved LOIs will be invited to submit a full application. The deadline to submit a LOI for the 2015 grant cycle is Tuesday, Sept. 30. Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
Join the ranks of other prestigious pain centers!
As one of APS's highest honors in the area of clinical treatment, the Clinical Centers of Excellence (CCOE) program awards multidisciplinary clinical programs based on quality of serves. The CCOE program awards both university and community-based programs. Any U.S.-based, multidisciplinary clinical program that provides direct patient care and is primarily focused on the treatment of pain that believe they meet the award criteria are encouraged to apply. Selection of awardees will be based on judgment of the quality of services provided and not size of program. The deadline to submit an application is Friday, Nov. 21. Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
True happiness is ... to enjoy the present, without anxious dependence upon the future."
-- Seneca,
Roman philosopher and playwright
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about APS ->About APS | Membership | Education | Resources | Journal of Pain
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks
Advertising:  Wynn Hansen
  P: 202.470.1149

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information